1.
Introduction 24 25 ACE inhibitory peptides derived from natural sources such as whey proteins could be 26 ACE, which is a constituent part of the rennin-angiotensin system, is a widely 38 accepted enzyme and is considered as the first line of therapy to treat hypertension 39 (Coppey et al, 2006) . The first ACE inhibitory peptide was isolated from snake venom 40 (Ferreira, 1965) and most antihypertensive drugs such as, captopril, lisinopril and 41 enalapril that can block the ACE mediated production of angiotensin II were designed 42 based on the snake venom peptide scaffold. The inactivation of ACE also results in 43 an increase in the nonapeptide bradykinin which is a vasodilator. Because of these 44 dual vascular and endothelial protective mechanism of ACE inhibition, the production 45 of nitric oxide is stimulated, vascular smooth muscle is relaxed and fibrinolysis is 46 increased (Ceconi, Francolini, Olivares, Comini, Bachetti & Ferrari, 2007) . 47
Micro QTOF electrospray ionisation tandem mass spectrometry (ESI 181

MS/MS) for amino acid sequencing of peptides derived mainly from CDP at 182
h 183 184
The freeze dried hydrolysate fractions were taken up in 100µl of HPLC grade water 185
and then an aliquot diluted 1:1 in water containing 0.1% formic acid for infusion into 186 the mass spectrometer. The mass spectrometer used was a Bruker MicroTOFQ II 187 (Bruker Daltonic, Bremen, Germany) equipped with electrospray ionisation source. 188
The samples were infused into the source, at 3µL/min, using a Harvard syringe pump 189 equipped with a 100µL syringe. The mass spectrometer had previously been 190 calibrated over a mass range of m/z 300-3000 using Agilent Tunemix™. 191 As each spectrum appeared a major peptide mass was isolated and fragmented in the 192 collision cell using sufficient energy to reduce the precursor ions to about 10% and to 193 produce an intense product ion spectrum. The accurate mass of each precursor ion 194 was then used to predict a formula to within approximately 20ppm accuracy and that 195 was used in combination with the MS/MS spectrum to obtain a partial or full amino 196 acid sequence. Software used was Bruker sequence editor and Mass Analysis Peptide 197
Sequence Prediction (MAPSP). 198 199
LC-ESI/MS method for peptide identification in β-lactoglobulin hydrolysate 200 201
Peptides of β-lactoglobulin hydrolysate and peptides in sweet whey were analysed by 202 LC-MS. Samples were reconstituted in HPLC grade water (1:100) and 2 µL injected. 203
The peptides were separated using reverse phase liquid chromatography (RP-HPLC) 204 with an Agilent 1100 HPLC system (Agilent Technologies, CA, USA). The column 205 used was a Nova-Pak C18 column (150 × 2.1 mm i.d.). A gradient solvent system was 206 applied with eluent "A" as 0.1% formic acid in water and eluent "B" 0.1% formic acid 207 in acetonitrile. The flow rate was 0.2 mL/min and, the column and the auto sampler 208 temperature were kept at 25 and 10 o C respectively. Eluent "A" was 98 to 55% for 45 209 min, 55 to 30% for 5 min and then kept at 30% for 5 min, 30 to 98% for 5 min and 210 98% for 15 min. The peaks were identified using a Bruker MicroTof QII high 211 resolution TOFMS equipped with an electrospray ionisation (ESI) source. The ion 212 spray voltage was held at 4500V in positive ion mode. The nebuliser gas was nitrogen 213 at a pressure of 1.0 bar; drying gas and temperature were 8 L/min and 180 o C 214 respectively. The instrument was interfaced to a computer running Bruker Data 215
Analysis software version 4 and data acquired over a mass range of 50-3000 Da. 216
Determination of ACE inhibitory activity 217
The ACE inhibitory activity of hydrolysates was measured following the HPLC based 218 method by Hyun and Shin (2000) with some modifications as described in 219 Welderufael and Jauregi (2010) . The enzymatic assay in this method was based on the 220 hydrolysis of the substrate, 5mM HHL in a 0.1M sodium phosphate buffer (pH 8.2) 221 with 0.3M NaCl by the ACE (60mU) which resulted in the production of hippuric 222 acid (HA). The hippuric acid was determined by RP-HPLC) as described in 223
Welderufael and Jauregi (2010) using a Dionex HPLC system (Camberley, UK) that 224 consisted of, a P680 HPLC pump, ASI-100 automated sample injector, thermostatted 225 column compartment TCC-100 and PDA-100 photodiode array detector and a C18 226 column (Ace5 250 x 4.6 mm). 227
228
The percentage of ACE inhibitory activity (ACEi %) was calculated based on the 229 hippuric acid liberated in the hydrolysate sample in relation to that in the control 230 sample (water). 231
232
The IC 50 of hydrolysates was determined by making serial dilutions (1/1, 1/2.5, 1/5, 233 1/10, 1/25 and 1/50) of the hydrolysate and plotting the inverse of their ACEi% versus 234 the inverse of their total protein concentration. The IC 50 was determined from the 235 resulting linear equation and expressed as µg/mL. 236
Sensory evaluation 237 238
The sensory evaluation of the products was reviewed and approved by the University 239 of Reading Ethics Committee. All participants gave written informed consent prior to 240 taking part in the study. Sensory discrimination tests were carried out for the two 241 different whey protein hydrolysates: (i) hydrolysate from CDP, and (ii) hydrolysate 242 from β-lactoglobulin. Prior to the sensory testing, the IC 50 values of both hydrolysates 243
were measured as 145 µg/mL for β-lactoglobulin derived hydrolysate and 288 µg/mL 244 for CDP derived hydrolysate. The hydrolysates were spray dried and incorporated into 245 pasteurised semi skimmed milk based at three different concentrations related to their 246 IC 50 : 100, 150 and 200 µg/mL for the β-lactoglobulin derived hydrolysate and 200, 247 300 and 400 µg/mL for the CDP derived hydrolysate. Samples were then stored at 248 4 °C for 24 h. Volunteers (n=39, untrained, age 18-60) were recruited from the 249 students and staff of the University of Reading. The sensory tests were carried out in 250 individual sensory booths under artificial daylight conditions. Samples (10 mL) were 251 coded with three-digit random number and held in plastic cups (30 mL). The 252 discrimination test followed a forced choice triangle test methodology, each panellist 253 receiving a triad of either two samples and a control (milk without hydrolysate) or 254 vice versa, sample presentation orders were balanced. Panellists were asked to move 255 the sample around the mouth and then expectorate. They were asked to select the 256 sample that was different out of the three and to describe the difference(s) perceived. 257
Water and crackers were used for palate cleansing in between the samples. Mass spectrometry analysis of peptide compositions in sweet whey confirmed the 312 presence of ten peptides ranging from 1881.1 to 20978.7 Da (see Figure 2) . Several 313 studies also indicated the presence of CDP in whey during cheese manufacturing as a 314 result of proteolysis of casein proteins by chymosin and endogenous milk enzymes 315 (Fox, 1993) . Particularly, plasmin activity could be high at conditions of rennet whey 316 preparation (35±2 o C and pH of milk) (Bastian and Brown, 1996) . 317 318 319
In our previous works (Welderufael and Jauregi, 2010 and Welderufael et al 2012) we 320 demonstrated that applying the integrative approach to whey resulted in the 321 production of two different hydrolysates, one from CDP and the other one from -322 lactoglobulin. In the present work we carried out the chemical characterisation of each 323 hydrolysate using mass spectrometer techniques in order to identify the main peptides 324 contributing to the ACE inhibitory activity measured in these hydrolysates. The positively charged amino acids such as arginine and lysine at the C-terminal 340 sequences were also reported to contribute towards ACE inhibitory or 341 antihypertensive effect (Cheung et al., 1980) . 342
343
The mass spectrometry analysis of the 2 and 6 h hydrolysates which had permeated 344 through the 1kDa ultrafiltration membrane show that both hydrolysates contain almost 345 the same peptide composition with peptides mainly from casein derived peptides (see 346 Table 2 for peptide compositon of the 2 h hydrolysate). 347 348 349
These two hydrolysates were fractionated into 8 fractions (see 2 h hydrolysate 350 chromatogram in Fig 3 ) and the three polar fractions A, B and C showed the highest 351 bioactivity. Particularly, fraction "B" in both, the 2 (see Table 2 and Figure 4 ) and 6 hhydrolysates (data not shown) contained IPP. This peptide has been identified as the 353 most potent ACE inhibitor from milk protein and it is derived from casein with an 354 IC 50 of 5µM (1.6 µg/mL) (Nakamura et al., 1995 be a contributor to ACE inhibitory activity as it is a fragment of the β-casein derived 359
hexapeptide Leu-His-Leu-Pro-Leu-Pro (LHLPLP). This hexapeptide has been 360 reported to have an IC 50 = 5.5 ± 0.5 µM = 3.8 µg/mL and has also shown a significant 361 blood pressure reduction effect at a dosage of 2 mg/kg (Quiros et al., 2009) . 362 363 Fraction "C" of the 2 h hydrolysate contained a β-lactoglobulin derived peptide Leu-364
Asp-Ile-Gln-Lys (LDIQK) while it was absent in the 6 h one. This pentapeptide is a 365 fraction of the ACE inhibitory hexapeptide Gly-Leu-Asp-Ile-Gln-Lys (GLDIQK) 366 which has been reported as a potent ACE inhibitor with an IC 50 of 27.5 μM or 18.5 367 µg/mL (Schlothauer, Schollum, Singh & Reid, 1999) . This same fraction, in both 368 hydrolysates, also contained an octapeptide Gln-Asp-Lys-Thr-Glu-Ile-Pro-Thr 369 (QDKTEIPT). In order to identify the main peptides responsible for the high 370 bioactivity of fraction C, the fraction of the 6 h hydrolysate was further fractionated 371 into four sub-fractions. This led to a fraction containing almost solely the octapeptide 372 QDKTEIPT and its IC 50 was 17.5 μg/mL (see Figure 5 and 6). So this proves that the 373 octapeptide was one of the main contributors to the IC 50 measured in fraction C (113 374 g/ml). Furthermore this peptide holds some structural similarities to other reported 375
ACE inhibitory peptides. Quirós et al. (2005) reported an ACE inhibitory peptide 376
Leu-Val-Tyr-Pro-Phe-Thr-Gly-Pro-Ile-Pro-Asn (LVYPFTGPIPN) from caprine kefirwith an IC 50 of 27.9 ± 2.3 μg/mL. This peptide has the same two penultimate 378 sequences Iso-leucine and Proline at the end of the C-terminal as the octapeptide 379 (QDKTEIPT). Moreover both peptides have uncharged and polar amino acids such as, 380 asparagine and threonine at the C-terminal end. Therefore, taking into account all the 381 above evidence both peptides LDIQK and QDKTEIPT are most likely to be the main 382 contributors to the high potency of fraction "C" of the 2 h hydrolysate. The 383 octapeptide QDKTEIPT is the main contributor to the potency of the 6 h hydrolysate. 384
385
The β-lactoglobulin derived tetrapeptide Lys-Ile-Pro-Ala (KIPA) in fraction "B" has a 386 very similar peptide sequence to a tripeptide reported by Abubakar and co-authors 387 (1998), the Ile-Pro-Ala (IPA), which was found to be a potent ACE inhibitor with 388 IC 50 = 141 µM (42 g/mL). 389 390 Fraction "A" also showed a high ACEi activity. Six peptide sequences Leu-Arg, Met-391 Ala-Pro-Lys, Ala-Met-Ala-Pro-Lys, Ile/Leu-Gln-Lys, Val-Ser-Lys and Thr-Val-Lys 392 were among the peptides identified in this fraction (see Figure 7 ). These peptides, like 393 the other well characterised ACE inhibitory peptides, also had some structural 394 features of ACE-inhibitors, e.g: the presence of charged followed by hydrophobic 395 amino acid residues in one of the penultimate sequences at the C-terminal sequences. terminal sequences (see Table 3 ). was identified in the current work that could be a potential contributor to ACE 441 inhibitory activity. Besides these interesting findings, the most interesting outcome of 442 this work is that unlike the complex peptide mixture produced from the standard β-443 lactoglobulin solution, the hydrolysates produced here were less complex and with 444 comparable IC 50 values (IC 50 = 128 µg/mL for the immobilized whey whereas 102 445 μg/mL for the standard β-lactoglobulin solution). 446 447
Impact of simulated gastrointestinal digestion on ACE inhibitory activity 448 449
Some food protein derived ACE inhibitory peptides may lose some of their ACE 450 inhibitory activity after oral administration due to further hydrolysis by 451 gastrointestinal enzymes (Walsh et al., 2004) . In this work, the ACE inhibitory 452 activity of CDP and β-lactoglobulin derived hydrolysates was further assessed after 453 the in-vitro simulated gastrointestinal digestion. The results showed no significant 454 differences in ACE inhibitory activity before and after the in-vitro digestion (see 455 Figure 9 ). This could be because either the potent peptides that contributed to the 456 inhibitory activity might be resistant to digestion or the digestion resulted in partial 457 hydrolysis and the active sequences were maintained intact with little impact on the 458 bioactivity. This was tested further by carrying out in-silico digestion of major 459 peptides in most active fractions. 460 461 3.4. In-silico digestibility study of CDP derived peptides 462 463 464
In order to assess the digestibility of specific peptides present in the hydrolysates, in-465 silico digestion of individual peptides was carried out following the method in section 466 2.2.7.2. Furthermore the ACE inhibitory activity of the peptides produced after 467 digestion was predicted following method in 2.2.7.3. Out of 25 peptide sequences 468 reported in the 2 h hydrolysate, 9 of the peptides were found to be resistant to 469 digestive enzymes including the most potent ACE inhibitory tripeptide IPP while only 470 4 were completely digested. Twelve peptides were partially hydrolysed (see Table 4 ) 471 but their C-terminal sequences remained intact. Furthermore, out of the ten peptides 472 that were mainly derived from β-lactoglobulin, only two were completely digested, 473 three were resistant to gastrointestinal digestion while five of the peptides were 474 partially hydrolysed. The three peptides resistant to the digestive enzymes were: Ile-475
Ile-Ala-Glu, Ile-Val-Thr-Gln and Val-Ala-Gln-Thr (see Table 3 ). 476
477
The octa-peptide Gln-Asp-Lys-Thr-Glu-Ile-Pro-Thr that was predominant in the 478 active fraction "Fraction C" (Table 2 and table 4) The peptide Ile-Ile-Ala-Glu-Lys-Thr (IIAEKT) was susceptible to partial digestion 498 and was predicted to loose threonine from the end of the Carboxyl-terminal. This 499 fragment, IIAEK (lactostatin) was reported to exhibit a greater hypercholesterolemia 500 effect even when compared to the drug β-sitosterol as tested in rats (Nagaoka et al., 501 2001) . 502 503 Interestingly the findings from the in-vitro and in-silico digestibility studies were in 504 agreement as using both methods it was found that digestion of the hydrolysates 505 resulted in no loss of ACE inhibitory activity. 506
Sensory evaluation 507
Sensory is one of the most important aspects that need to be given consideration after 508 the production of hydrolysates. The release of bitter tasting peptides can significantly 509 affect the sensory attributes of the resultant hydrolysate and subsequently alter the 510 quality of products to which they are added. Therefore to assess whether the 511 hydrolysate products developed in this study had any effect on a typical beverage, 512 they were added into milk which was subjected to a sensory discrimination test. Milk 513 with hydrolysate addition was compared to a control milk sample with no addition. 514 515 516 517 518 519 520 521 522
Overall, for the CDP and β-lactoglobulin derived hydrolysates no significant 523 differences were found in perception between any of the three samples and the control 524 milk samples (see tables 5 and 6). However the sample with the lowest level of 525 hydrolysate was the most different to the control milk (p=0.066). With the relatively 526 low number of assessors (n=39) used in the trials, although there was no significant 527 differences in perception found, the samples could not be declared with confidence to 528 be perceptually identical, as either the proportion of discriminators amongst the 529 population was too high (>30%), or at a risk level of 10 % (type II error) the 530 probability of correctly identifying a sample from the control in any individual trial 531 was too high (the upper bound limit), or the probability of obtaining a result higher 532 than the upper bound limit was too high. The results of this pilot study must be scaled 533 up and taken to a larger consumer trial in order to prove the samples with hydrolysate 534 are perceptually identical to milk. 535 CDP derived hydrolysates: Three different concentrations of hydrolysate derived 536 from CDP were tested for sensory attributes. The IC 50 of CDP derived hydrolysate 537 was 288 µg/mL. Therefore we used three different concentrations, (i) 200 µg/mL (ii) 538 300 µg/mLand (ii) 400 µg/mL. 539
Although there was no statistical significant difference between the control and the 540 three different hydrolysate concentrations (see Table 5 ), comments given by the 541 assessors were compiled. The 200 µg/mL and the 300 µg/mL were described as less 542 sweet compared to the control, by 4 and 3 assessors respectively, and 3 assessors 543 described the taste and odour of the 400 µg/mL as less milky. However, there were no 544 comments concerning off notes, taints or bitter taste. These findings are very sequence. Furthermore, they found that peptides with arginine followed by proline 566 had a strong bitter taste. 567 568 β-lactoglobulin derived hydrolysate: Three different concentrations were also tested 569 for the β-lactoglobulin derived hydrolysate. The IC 50 of this hydrolysate was 145 570 µg/mL. Therefore three different concentrations were chosen in relation to its IC 50 ; (i) 571 100 µg/mL, (ii) 150 µg/mL (iii) 200 µg/mL. The result showed statistically no 572 significant difference between the three different concentrations and the control (see 573   Table 6 ). From the compiled comments, only 2 assessors out of 39 reported adverse 574 tastes; one reported sour for the 100 µg/mL sample and the other reported bitter for 575 the 150 µg/mL. Moreover, only 4 assessors described the 300 µg/mL samples as less 576 sweet compared to the control. 577
578
A total of ten major peptides were identified in this hydrolysate and out of the ten 579 peptides, only three peptides VAGT, RL and LDAQ were free from the above 580 This study demonstrated that the production process applied in this work resulted in 593
hydrolysates of high ACE inhibitory activity. The fractionation of hydrolysates by 594 preparative HPLC and the use of MS techniques helped to identify major bioactive 595
peptides. This together with available structure activity relationship data including 596 QSAR enable identification of main peptides contributing to the ACE inhibitory 597 activity of hydrolysates. Among these potent peptides some novel sequences were 598 identified such as, VSK, IIAE, QDKTEIPT, KPTPEGDLEILL and LDIQK . Also the 599 well known ACE inhibitory peptide IPP was identified in the CDP derived 600
hydrolysates. The in-vitro simulated gastrointestinal digestibility study showed that 601 there was no significant change in the ACE inhibitory activity of the hydrolysates 602
This was also in agreement with the findings from the in-silico digestion study. The 603 in-silico digestion of both hydrolysates predicted that most of the peptides were either 604 resistant or only susceptible to partial hydrolysis and the resulting fragments were 605 predicted to be ACE inhibitory. Hence, no overall loss of ACE inhibitory activity was 606 predicted. The sensory evaluation of the hydrolysates showed no significant 607 difference between the reconstituted hydrolysate products and the control. This might 608 be due to low structural similarity of the peptides with that of bitterness causing 609 Table 2 IC 50 (µg/mL) value and the major peptides of the three active fractions of the 2 h hydrolysate that were permeated through the 1kDa ultrafiltration membrane followed by fractionation using semi-prep RP-HPLC. Table 4 In silico digestion of the major peptides identified in the active fraction of the 2 h and 6 h hydrolysate permeated through the 1kDa ultrafiltration membrane (P1 and P2).
TABLES
Where: * stands for peptides that were common to both hydrolysates at 2 and 6 h and ↓chymotrypsin, ↑pepsin, →Trypsin are cleavage sites of these enzymes. The maximum acceptable proportion of the population that can distinguish between the samples (typically an acceptable maximum set at 0.3 or 30 %) c The upper bound is the probability of a correct trial d The probability of obtaining a higher upper bound value in 39 trials (i.e. of obtaining a less satisifactory result) Table 6 Sensory discrimination of β-lactoglobulin derived hydrolysate; where β-LG100, β-
LG150 and β-LG200 were 100 µg/mL, 150 µg/mL and 200 µg/mL respectively. N is number of panellists. 
FIGURES:
Figure 1 
